1952 - Fellow of the American Association for the Advancement of Science (AAAS)
His primary scientific interests are in Osteoporosis, Internal medicine, Bone mineral, Bone density and Surgery. His Osteoporosis study incorporates themes from Placebo, Physical therapy, Bone remodeling and Urology. Many of his studies involve connections with topics such as Endocrinology and Internal medicine.
His study in Bone mineral is interdisciplinary in nature, drawing from both Relative risk and Orthopedic surgery. His biological study spans a wide range of topics, including Teriparatide, Radiology and Densitometry. In his study, Postmenopausal women is inextricably linked to Intensive care medicine, which falls within the broad field of Surgery.
Paul D. Miller focuses on Osteoporosis, Internal medicine, Bone mineral, Surgery and Bone density. Paul D. Miller interconnects Placebo, Physical therapy, Bone remodeling and Urology in the investigation of issues within Osteoporosis. He focuses mostly in the field of Internal medicine, narrowing it down to matters related to Endocrinology and, in some cases, Parathyroid hormone.
His Bone mineral research focuses on Densitometry and how it relates to Bone mass. The concepts of his Surgery study are interwoven with issues in Tolerability, Adverse effect, Ibandronic acid and Bone disease. His Bone density study incorporates themes from Radiology, MEDLINE and Family medicine.
Paul D. Miller mainly investigates Osteoporosis, Internal medicine, Abaloparatide, Bone mineral and Urology. His work on Osteoporosis is being expanded to include thematically relevant topics such as Placebo. Paul D. Miller works mostly in the field of Internal medicine, limiting it down to topics relating to Endocrinology and, in certain cases, Parathyroid hormone.
His Bone mineral research includes themes of Height loss and Lumbar spine, Surgery. His Surgery research incorporates elements of Bisphosphonate and MEDLINE. His Urology research includes elements of Anabolism and Bone regeneration.
Osteoporosis, Teriparatide, Internal medicine, Surgery and Placebo are his primary areas of study. Paul D. Miller works mostly in the field of Osteoporosis, limiting it down to topics relating to Urology and, in certain cases, Denosumab, as a part of the same area of interest. Paul D. Miller has included themes like Cortical bone, Biopsy and Bone formation in his Teriparatide study.
His research on Internal medicine often connects related areas such as Endocrinology. His Surgery research is multidisciplinary, relying on both Bisphosphonate, Cohort study and MEDLINE. Paul D. Miller usually deals with Placebo and limits it to topics linked to Postmenopausal osteoporosis and Drug Substitution and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial
Steven T. Harris;Nelson B. Watts;Harry K. Genant;Clark D. McKeever.
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Michael R. McClung;Piet Geusens;Paul D. Miller;Hartmut Zippel.
The New England Journal of Medicine (2001)
Primer on the metabolic bone diseases and disorders of mineral metabolism
John P. Bilezikian;Roger Bouillon;Thomas Clemens;Juliet Compston.
Papagerakis, P; Mitsiadis, T A (2008). Primer on the metabolic bone diseases and disorders of mineral metabolism. In: Rosen, Clifford J; Compston, Juliet E; Lian, Jane B. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: John Wiley & Sons, 491-496. (2013)
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
Charles H Chesnut;Stuart Silverman;Kim Andriano;Harry Genant.
The American Journal of Medicine (2000)
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
N B Watts;S T Harris;H K Genant;R D Wasnich.
The New England Journal of Medicine (1990)
Alendronate for the treatment of osteoporosis in men
Eric Orwoll;Mark Ettinger;Stuart Weiss;Paul Miller.
The New England Journal of Medicine (2000)
Bone mineral density thresholds for pharmacological intervention to prevent fractures
Ethel S. Siris;Ya Ting Chen;Thomas A. Abbott;Elizabeth Barrett-Connor.
JAMA Internal Medicine (2004)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
Paul D. Miller;Michael A. Bolognese;E. Michael Lewiecki;Michael R. McClung.
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Paul D. Miller;Gary Hattersley;Bente Juel Riis;Gregory C. Williams.
Osteoporosis and Fracture Risk in Women of Different Ethnic Groups
Elizabeth Barrett-Connor;Ethel S Siris;Lois E Wehren;Paul D Miller.
Journal of Bone and Mineral Research (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: